XML 91 R60.htm IDEA: XBRL DOCUMENT v3.21.1
Financial Instruments Financial Instruments (Details Textual 2) - USD ($)
$ / shares in Units, shares in Millions, number in Millions, $ in Millions
1 Months Ended 3 Months Ended
Nov. 30, 2020
Apr. 30, 2020
Feb. 29, 2020
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Business Acquisition [Line Items]            
Proceeds from sales of strategic investments       $ 91.2 $ 0.5  
Sage Therapeutics Inc.            
Business Acquisition [Line Items]            
Global Licensing Collaboration Agreement, Amount, Shares Purchased $ 650.0          
Global Licensing Collaboration Agreement, Shares, Purchased 6.2          
Global Licensing Collaboration Agreement, Purchase Price Per Share $ 104.14          
Dividend yield percentage       0.00%    
Sangamo Therapeutics, Inc. Agreement            
Business Acquisition [Line Items]            
Global Licensing Collaboration Agreement, Amount, Shares Purchased     $ 225.0      
Global Licensing Collaboration Agreement, Shares, Purchased     24.0      
Strategic Investments            
Business Acquisition [Line Items]            
Strategic investment portfolio       $ 1,493.1    
Other noncurrent assets | Strategic Investments            
Business Acquisition [Line Items]            
Strategic investment portfolio           $ 2,024.6
Denali Therapeutics            
Business Acquisition [Line Items]            
Investment in common stock, shares purchased       13.0    
Dividend yield percentage       0.00%    
Sangamo            
Business Acquisition [Line Items]            
Dividend yield percentage   0.00%